Description: Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Home Page: www.formycon.com
Fraunhoferstrasse 15
Planegg,
82152
Germany
Phone:
49 89 864 667 100
Officers
| Name | Title |
|---|---|
| Dr. Stefan Glombitza | CEO, COO & Member of Exec. Board |
| Dr. Friedrich-Wilhelm Steinweg | Co-Founder |
| Dr. Nicolas Combe Ph.D. | Co-Founder & CFO |
| Dr. Andreas Seidl | Chief Scientific Officer & Member of Exec. Board |
| Ms. Nicola Mikulcik | Chief Bus. Officer & Member of Exec. Board |
| Sabrina Muller | Sr. Mang. of Corp. Communications & Investor Relations |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 14.8515 |
| Price-to-Book MRQ: | 3.2308 |
| Price-to-Sales TTM: | 38.8516 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 146 |